Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547700 · ClinicalTrials.gov registry record · Phase 1
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
A Phase 1 study of Lymphoma, T-Cell, Peripheral, sponsored by Ryan Wilcox.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 7
- Study locations
NCT03547700 is a Phase 1 study of Lymphoma, T-Cell, Peripheral that is active but no longer recruiting, run by Ryan Wilcox. The registered enrollment target is 11 participants, below the 331-participant average among 6 other Lymphoma, T-Cell, Peripheral trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT03547700, a Phase 1 study of Lymphoma, T-Cell, Peripheral, is active but no longer recruiting, sponsored by Ryan Wilcox.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 7
- Study locations
Study Summary
Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study.
Conditions Studied
Interventions
- DRUG Romidepsin
- DRUG Ixazomib
Study Locations (7)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Karmanos Cancer Center (Wayne State University) - Detroit
Illinois
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Minnesota
- University of Minnesota - Minneapolis
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2021-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03547700
The ClinicalTrials.gov registry entry for NCT03547700 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 6 other Lymphoma, T-Cell, Peripheral trials with a reported enrollment target (97% lower). The listed sponsor is Ryan Wilcox, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, T-Cell, Peripheral appearing as the primary indexed condition, and to 2 interventions - of which Romidepsin is the first listed.
NCT03547700 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Michigan, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT03547700 about?
NCT03547700 is a clinical study titled "Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)". Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase ...
What is the current status of trial NCT03547700?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2018-09-26. Estimated completion is 2021-07.
What conditions does trial NCT03547700 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell, Peripheral.
What interventions are being tested in trial NCT03547700?
The interventions under investigation include: Romidepsin (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03547700?
This trial is sponsored by Ryan Wilcox, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03547700 being conducted?
This trial has 7 study locations across Illinois, Indiana, Iowa, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell, Peripheral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
COMPLETED · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
COMPLETED
-
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.